A clinician's guide for counseling patients on results of a multigene pharmacogenomic panel.

Teresa T Ho, Gillian Bell, Roseann S Gammal, David Gregornik, Dyson T Wake, Henry M Dunnenberger
{"title":"A clinician's guide for counseling patients on results of a multigene pharmacogenomic panel.","authors":"Teresa T Ho,&nbsp;Gillian Bell,&nbsp;Roseann S Gammal,&nbsp;David Gregornik,&nbsp;Dyson T Wake,&nbsp;Henry M Dunnenberger","doi":"10.1093/ajhp/zxac189","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This article explores approaches to pharmacogenomic counseling for patients who have undergone multigene panel testing by describing the collective experience of 5 institutions.</p><p><strong>Summary: </strong>Multigene panel pharmacogenomic testing has the potential to unlock a myriad of information about a patient's past, present, and future drug response. The multifaceted nature of drug response coupled with the complexity of genetic results necessitates some form of patient education through pharmacogenomic counseling. Published literature regarding disclosure of pharmacogenomic test results is limited. This article compares the counseling practices of pharmacists from 5 different institutions with pharmacogenomics clinics whose experience represents perspectives ranging from academia to community clinical environments. Overarching counseling themes discussed during result disclosure center around (1) pharmacogenomic results, (2) gene-drug interactions, (3) gene-drug-drug interactions, (4) drug changes (5) future, familial, or disease-risk implications, (6) updates in the interpretation and application of pharmacogenomic results, (7) gauging patient comprehension, and (8) sharing results and supplemental information.</p><p><strong>Conclusion: </strong>Dedicating time to counseling patients on the results of a multigene pharmacogenomic panel is important given the lifelong applications of a test that is generally performed only once. The content and methods of disclosing test results shared by the experiences of pharmacists at 5 different institutions serve as guide to be further refined as research addresses effective communication strategies that enhance patient comprehension of pharmacogenomic results.</p>","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"1634-1644"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxac189","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This article explores approaches to pharmacogenomic counseling for patients who have undergone multigene panel testing by describing the collective experience of 5 institutions.

Summary: Multigene panel pharmacogenomic testing has the potential to unlock a myriad of information about a patient's past, present, and future drug response. The multifaceted nature of drug response coupled with the complexity of genetic results necessitates some form of patient education through pharmacogenomic counseling. Published literature regarding disclosure of pharmacogenomic test results is limited. This article compares the counseling practices of pharmacists from 5 different institutions with pharmacogenomics clinics whose experience represents perspectives ranging from academia to community clinical environments. Overarching counseling themes discussed during result disclosure center around (1) pharmacogenomic results, (2) gene-drug interactions, (3) gene-drug-drug interactions, (4) drug changes (5) future, familial, or disease-risk implications, (6) updates in the interpretation and application of pharmacogenomic results, (7) gauging patient comprehension, and (8) sharing results and supplemental information.

Conclusion: Dedicating time to counseling patients on the results of a multigene pharmacogenomic panel is important given the lifelong applications of a test that is generally performed only once. The content and methods of disclosing test results shared by the experiences of pharmacists at 5 different institutions serve as guide to be further refined as research addresses effective communication strategies that enhance patient comprehension of pharmacogenomic results.

临床医生的指导,咨询患者的结果多基因药物基因组小组。
目的:本文通过描述5家机构的集体经验,探讨对接受多基因小组检测的患者进行药物基因组学咨询的方法。摘要:多基因小组药物基因组学检测有可能解开关于患者过去、现在和未来药物反应的无数信息。药物反应的多面性,加上遗传结果的复杂性,需要通过药物基因组学咨询对患者进行某种形式的教育。已发表的关于药物基因组学检测结果披露的文献是有限的。本文比较了来自5个不同机构的药剂师与药物基因组学诊所的咨询实践,他们的经验代表了从学术界到社区临床环境的观点。结果披露期间讨论的主要咨询主题围绕(1)药物基因组学结果,(2)基因-药物相互作用,(3)基因-药物-药物相互作用,(4)药物变化,(5)未来,家族或疾病风险影响,(6)药物基因组学结果解释和应用的更新,(7)衡量患者理解,(8)分享结果和补充信息。结论:考虑到一项通常只进行一次的测试的终身应用,花时间就多基因药物基因组学小组的结果向患者提供咨询是很重要的。5家不同机构的药师分享的检测结果披露的内容和方法可以作为进一步完善的指南,因为研究涉及有效的沟通策略,以增强患者对药物基因组学结果的理解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信